Psoriasis: risankizumab tops adalimumab in phase 3 trial

Takeaway

Risankizumab (Skyrizi) shows superior efficacy to adalimumab (Humira) in patients with moderate-to-severe plaque psoriasis, according to the multinational phase 3 IMMvent trial.

Why this matters

This is the first head-to-head trial comparing these 2 biologic therapies for psoriasis.

Key results

Risankizumab was associated with better efficacy compared with adalimumab at week 16.
- 72% vs 47% of patients achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI-90) (P<.0001>
- 84% vs 60% of patients achieved static Physician’s Global Assessment (sPGA) scores of clear or almost clear (P<.0001>
Adalimumab intermediate responders who switched to risankizumab at week 16 showed a higher PASI 90 rate (66% vs 21%; P<.0001 and spga clear rate vs compared with patients who continued adalimumab at week>
Risankizumab and adalimumab were associated with similar rates of adverse events at week 16 (56% vs 57%).

Study design

605 patients with moderate-to-severe plaque psoriasis were randomly assigned to risankizumab (n=301) or adalimumab (n=304) through 16 weeks.
At week 16, 102 patients with an intermediate response to adalimumab were re-randomly assigned to risankizumab (n=51) or adalimumab (n=51) through week 44.
Funding: AbbVie, Boehringer Ingelheim.

Limitations

Only healthcare professionals with a Univadis account have access to this article.

You have reached your limit of complementary articles

Free Sign Up Available exclusively to healthcare professionals

Don’t have an account?